Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
企業コードCADL
会社名Candel Therapeutics Inc
上場日Jul 27, 2021
最高経営責任者「CEO」Tak (Paul Peter)
従業員数38
証券種類Ordinary Share
決算期末Jul 27
本社所在地117 Kendrick Street,
都市NEEDHAM
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02494
電話番号16179165445
ウェブサイトhttps://www.candeltx.com/
企業コードCADL
上場日Jul 27, 2021
最高経営責任者「CEO」Tak (Paul Peter)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし